Park, Sin-Aye Sung, Nam Ji Choi, Bae-Jung Kim, Wonki Kim, Seung Hyeon Surh, Young-Joon
Published in
British Journal of Cancer
BackgroundGremlin-1 (GREM1), one of the bone morphogenetic protein antagonists, is involved in organogenesis, tissue differentiation and kidney development. However, the role of GREM1 in cancer progression and its underlying mechanisms remain poorly understood.MethodsThe role of GREM1 in breast cancer progression was assessed by measuring cell viab...
Wang, Lei Wang, Quanren Xu, Piaopiao Fu, Li Li, Yun Fu, Haoyu Quan, Haitian Lou, Liguang
Published in
British Journal of Cancer
BackgroundTrastuzumab–emtansine (T-DM1), one of the most potent HER2-targeted drugs, shows impressive efficacy in patients with HER2-positive breast cancers. However, resistance inevitably occurs and becomes a critical clinical problem.MethodsWe modelled the development of acquired resistance by exposing HER2-positive cells to escalating concentrat...
Kim, Min Hwan Kim, Jae-Hwan Lee, Ji Min Choi, Jae Woo Jung, Dongmin Cho, Hojin Kang, Hyundeok Hong, Min Hee Heo, Su Jin Kim, Se Heon
...
Published in
British Journal of Cancer
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Saini, Kamal S. Lanza, Carlo Romano, Marco de Azambuja, Evandro Cortes, Javier de las Heras, Begoña de Castro, Javier Lamba Saini, Monika Loibl, Sibylle Curigliano, Giuseppe
...
Published in
British Journal of Cancer
Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
Rezende, Leandro F. M. Lee, Dong Hoon Keum, NaNa Wu, Kana Eluf-Neto, José Tabung, Fred K. Giovannucci, Edward L.
Published in
British Journal of Cancer
BackgroundMuscle-strengthening activities have been recommended for health benefits. However, it is unclear whether resistance training is associated with cancer risk, independent of total physical activity.MethodsA prospective cohort study followed 33,787 men from the Health Professionals Follow-up Study (1992–2014). Cumulative average of resistan...
Togo, Maria Yokobori, Takehiko Shimizu, Kimihiro Handa, Tadashi Kaira, Kyoichi Sano, Takaaki Tsukagoshi, Mariko Higuchi, Tetsuya Yokoo, Satoshi Shirabe, Ken
...
Published in
British Journal of Cancer
BackgroundLately, immune checkpoint proteins, such as programmed death 1 (PD-1) and its ligand-1 (PD-L1), have garnered attention as a new target in oral squamous cell carcinoma (OSCC). Reportedly, fluoro-d-glucose (FDG)-uptake alteration by anti-PD-1 antibody treatment depicts the response in patients with lung cancer. This study aims to elucidate...
Mukai, Hirofumi Yamaguchi, Takeshi Takahashi, Masato Hozumi, Yasuo Fujisawa, Tomomi Ohsumi, Shozo Akabane, Hiromitsu Nishimura, Reiki Takashima, Tsutomu Park, Youngjin
...
Published in
British Journal of Cancer
BackgroundThe effectiveness of a therapeutic strategy that switches chemotherapy, based on Ki-67 tumour expression after initial therapy, relative to that of standard chemotherapy, has not been evaluated.MethodsPatients were randomly assigned to the control arm or the Ki-67 response-guided arm (Ki-67 arm). Primary tumour biopsies were obtained befo...
Hong, David S. Kang, Yoon-Koo Borad, Mitesh Sachdev, Jasgit Ejadi, Samuel Lim, Ho Yeong Brenner, Andrew J. Park, Keunchil Lee, Jae-Lyun Kim, Tae-You
...
Published in
British Journal of Cancer
BackgroundIn this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours.MethodsAdults with various solid tumours refractory to standard treatments were enrolled in 3 + 3 dose-esc...
Xue, Yue Lian, Wenwen Zhi, Jiaqi Yang, Wenjuan Li, Qianjin Guo, Xingyi Gao, Jiahao Qu, Hao Lin, Weiqiang Li, Zhongqi
...
Published in
British Journal of Cancer
BackgroundTamoxifen resistance remains a significant clinical challenge for the therapy of ER-positive breast cancer. It has been reported that the upregulation of transcription factor SOX9 in ER+ recurrent cancer is sufficient for tamoxifen resistance. However, the mechanisms underlying the regulation of SOX9 remain largely unknown.MethodsThe acet...
Sim, Sung Hoon Park, In Hae Jung, Kyung Hae Kim, Sung-Bae Ahn, Jin-Hee Lee, Kyung-Hun Im, Seock-Ah Im, Young-Hyuck Park, Yeon Hee Sohn, Joohyuk
...
Published in
British Journal of Cancer
BackgroundThe continuum of anti-HER2 agents is a standard treatment of HER2 + metastatic breast cancer (MBC). This study evaluated the efficacy of lapatinib plus vinorelbine in patients progressed on both trastuzumab and lapatinib treatments.MethodsA total of 149 patients were randomly assigned to lapatinib with vinorelbine (LV) (n = 75; lapatinib,...
